CG Invites Co., Ltd.
Financials
Valuation Metrics
CG Invites Co., Ltd.'s Market Cap is ₩753B. At end of 2025 it was ₩1143B. Ranked #1478 of 2,421 in KR market (top 61%), #856 of 1,640 on KOSDAQ (top 52%), #159 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 69%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 75.28B KRW | KR#1,478/2,421 Sec#159/231 |
| Revenue | 27.03B KRW | KR#2,067/2,421 Sec#144/231 |
| Net Income | -8.75B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 220.05B KRW | KR#1,248/2,421 Sec#91/231 |
| Net Assets | 105.33B KRW | KR#1,377/2,421 Sec#108/231 |
| Employees | 80 | KR#1,810/2,421 Sec#152/231 |
| Value | ||
| P/B | 0.71x | KR#1,152/2,421 Sec#66/231 |
| P/S | 2.78x | KR#1,954/2,421 Sec#117/231 |
| FCF Yield | -26.68% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -8.31% | KR#1,899/2,421 Sec#139/231 |
| ROA | -3.98% | KR#1,883/2,421 Sec#134/231 |
| Op. Margin | -83.80% | KR#2,290/2,421 Sec#170/231 |
| Revenue Growth | 98.44% | KR#88/2,421 Sec#18/231 |
| Financial Health | ||
| Debt Ratio | 108.93% | KR#1,627/2,421 Sec#187/231 |
| Total Debt | 43.59B KRW | KR#1,053/2,421 Sec#73/231 |
| FCF | -20.08B KRW | KR#1,894/2,421 Sec#179/231 |
| Cash | 5.94B KRW | KR#1,945/2,421 Sec#174/231 |
| Current Ratio | 0.34x | KR#2,200/2,421 Sec#214/231 |
| Performance | ||
| 1Y Return | -45.85% | KR#1,959/2,421 Sec#170/231 |
| 1M Return | 28.65% | KR#144/2,421 Sec#11/231 |
| From 52W High | -47.08% | KR#1,253/2,421 Sec#94/231 |
| 1Y MDD | -59.01% | KR#1,419/2,421 Sec#113/231 |
| Trading | ||
| Volume | 85,591 shares | KR#856/2,421 Sec#80/231 |
| Trading Value | 84.4M KRW | KR#1,629/2,421 Sec#160/231 |
| Foreign Own. | 2.29% | KR#1,532/2,421 Sec#144/231 |
| Per Share | ||
| EPS | -114 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,370 KRW | KR#2,222/2,421 Sec#196/231 |
Company Info
CG Invites, established in 2000, changed its name in 2023 and was listed on KOSDAQ in 2006. The bio company specializes in digital genome new drug development, Printed Circuit Board/hot pack manufacturing, and healthcare solutions. It commercialized the anti-inflammatory analgesic 'Acellex' as South Korea's first new drug and is conducting US FDA clinical trials for molecular targeted anti-cancer drugs. CG Invites is establishing a healthcare platform that merges genome analysis with artificial intelligence and big data, aiming to become a leading company in the genome industry. The company is headquartered in Gangseo-gu, Seoul.